ATE270271T1 - Sulfonamidhydroxamate - Google Patents
SulfonamidhydroxamateInfo
- Publication number
- ATE270271T1 ATE270271T1 AT99963530T AT99963530T ATE270271T1 AT E270271 T1 ATE270271 T1 AT E270271T1 AT 99963530 T AT99963530 T AT 99963530T AT 99963530 T AT99963530 T AT 99963530T AT E270271 T1 ATE270271 T1 AT E270271T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonamide
- hydroxamates
- sulfonamide hydroxamates
- procollagen
- char
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title abstract 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 abstract 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Detergent Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11331198P | 1998-12-22 | 1998-12-22 | |
| US14705399P | 1999-08-03 | 1999-08-03 | |
| PCT/EP1999/009920 WO2000037436A1 (en) | 1998-12-22 | 1999-12-14 | Sulfonamide hydroxamates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE270271T1 true ATE270271T1 (de) | 2004-07-15 |
Family
ID=26810914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99963530T ATE270271T1 (de) | 1998-12-22 | 1999-12-14 | Sulfonamidhydroxamate |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1149072B1 (de) |
| JP (1) | JP2002533322A (de) |
| KR (1) | KR20010101312A (de) |
| CN (1) | CN1331674A (de) |
| AT (1) | ATE270271T1 (de) |
| AU (1) | AU769319B2 (de) |
| BR (1) | BR9916504A (de) |
| CA (1) | CA2355902A1 (de) |
| CZ (1) | CZ20012294A3 (de) |
| DE (1) | DE69918465D1 (de) |
| HK (1) | HK1042691A1 (de) |
| HR (1) | HRP20010443A2 (de) |
| HU (1) | HUP0104658A3 (de) |
| IL (1) | IL143625A0 (de) |
| MA (1) | MA26767A1 (de) |
| NO (1) | NO20013100L (de) |
| NZ (1) | NZ512292A (de) |
| PL (1) | PL349449A1 (de) |
| RU (1) | RU2232751C2 (de) |
| TR (1) | TR200101868T2 (de) |
| WO (1) | WO2000037436A1 (de) |
| YU (1) | YU44901A (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| GB0108097D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| US6645993B2 (en) | 2001-03-30 | 2003-11-11 | Warner-Lambert Company | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| CA2449999C (en) * | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| BR0308908A (pt) | 2002-04-03 | 2005-01-04 | Topotarget Uk Ltd | Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase |
| MXPA05008106A (es) * | 2003-02-18 | 2005-09-21 | Pfizer | Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean. |
| EP2181995A3 (de) * | 2003-09-03 | 2010-06-16 | Glaxo Group Limited | Salze und kristalline Forme von Mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetat |
| US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| EP1740530B8 (de) * | 2004-03-16 | 2017-03-01 | Temple University - Of The Commonwealth System of Higher Education | Substituierte phenoxy- und phenylthioderivate zur behandlung von proliferativen erkrankungen |
| ITFI20040174A1 (it) * | 2004-08-03 | 2004-11-03 | Protera S R L | Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi |
| MX2011000512A (es) | 2008-07-14 | 2011-02-24 | Novartis Ag | Inhibidores selectivos de mmp-12 y mmp-13 basados en acido hidroxamico. |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US8354548B2 (en) * | 2010-02-19 | 2013-01-15 | Bristol-Myers Squibb Company | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase |
| JPWO2012165262A1 (ja) * | 2011-05-27 | 2015-02-23 | 国立大学法人徳島大学 | ベンジルアミン誘導体 |
| CN106103431B (zh) | 2014-01-10 | 2019-03-15 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 羟基甲酰胺衍生物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| CN1198096A (zh) * | 1995-08-08 | 1998-11-04 | 菲布洛根有限公司 | 用于治疗与胶原蛋白过量产生有关的疾病的c－蛋白酶抑制剂 |
-
1999
- 1999-12-14 HR HR20010443A patent/HRP20010443A2/hr not_active Application Discontinuation
- 1999-12-14 BR BR9916504-0A patent/BR9916504A/pt not_active IP Right Cessation
- 1999-12-14 HK HK02104473.6A patent/HK1042691A1/zh unknown
- 1999-12-14 NZ NZ512292A patent/NZ512292A/xx unknown
- 1999-12-14 JP JP2000589508A patent/JP2002533322A/ja active Pending
- 1999-12-14 IL IL14362599A patent/IL143625A0/xx unknown
- 1999-12-14 TR TR2001/01868T patent/TR200101868T2/xx unknown
- 1999-12-14 WO PCT/EP1999/009920 patent/WO2000037436A1/en not_active Ceased
- 1999-12-14 DE DE69918465T patent/DE69918465D1/de not_active Expired - Lifetime
- 1999-12-14 EP EP99963530A patent/EP1149072B1/de not_active Expired - Lifetime
- 1999-12-14 KR KR1020017007861A patent/KR20010101312A/ko not_active Withdrawn
- 1999-12-14 CA CA002355902A patent/CA2355902A1/en not_active Abandoned
- 1999-12-14 RU RU2001119461/04A patent/RU2232751C2/ru not_active IP Right Cessation
- 1999-12-14 AT AT99963530T patent/ATE270271T1/de not_active IP Right Cessation
- 1999-12-14 PL PL99349449A patent/PL349449A1/xx not_active Application Discontinuation
- 1999-12-14 HU HU0104658A patent/HUP0104658A3/hu unknown
- 1999-12-14 CN CN99814937A patent/CN1331674A/zh active Pending
- 1999-12-14 AU AU19792/00A patent/AU769319B2/en not_active Ceased
- 1999-12-14 YU YU44901A patent/YU44901A/sh unknown
- 1999-12-14 CZ CZ20012294A patent/CZ20012294A3/cs unknown
-
2001
- 2001-06-20 MA MA26245A patent/MA26767A1/fr unknown
- 2001-06-21 NO NO20013100A patent/NO20013100L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1149072B1 (de) | 2004-06-30 |
| JP2002533322A (ja) | 2002-10-08 |
| YU44901A (sh) | 2003-12-31 |
| DE69918465D1 (de) | 2004-08-05 |
| AU1979200A (en) | 2000-07-12 |
| NZ512292A (en) | 2004-03-26 |
| HUP0104658A3 (en) | 2005-12-28 |
| TR200101868T2 (tr) | 2001-11-21 |
| NO20013100D0 (no) | 2001-06-21 |
| BR9916504A (pt) | 2001-09-11 |
| AU769319B2 (en) | 2004-01-22 |
| HK1042691A1 (zh) | 2002-08-23 |
| CA2355902A1 (en) | 2000-06-29 |
| RU2232751C2 (ru) | 2004-07-20 |
| CN1331674A (zh) | 2002-01-16 |
| WO2000037436A1 (en) | 2000-06-29 |
| NO20013100L (no) | 2001-08-21 |
| PL349449A1 (en) | 2002-07-29 |
| HRP20010443A2 (en) | 2002-06-30 |
| MA26767A1 (fr) | 2004-12-20 |
| IL143625A0 (en) | 2002-04-21 |
| EP1149072A1 (de) | 2001-10-31 |
| KR20010101312A (ko) | 2001-11-14 |
| HUP0104658A2 (en) | 2002-06-29 |
| CZ20012294A3 (cs) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26767A1 (fr) | Hydroxamates de sulfonamide | |
| EA200200938A1 (ru) | Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение | |
| DK0889876T3 (da) | Meta-substituerede phenylensulfonamidderivater | |
| EA200400815A1 (ru) | Контролируемый синтез зипразидона и его композиции | |
| ATE273305T1 (de) | Thrombin-inhibitoren | |
| EA200200940A1 (ru) | Производные азетидина, способ их получения и содержащие их фармацевтические композиции | |
| DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| BG103964A (en) | SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS | |
| IL135536A0 (en) | Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same | |
| WO1999033858A3 (en) | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use | |
| EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
| EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| FI970317A0 (fi) | Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä | |
| TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
| EA200200774A1 (ru) | Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции | |
| CO5261493A1 (es) | Procedimiento y compuestos para la inhibicion de la mrp1 | |
| EA200100516A1 (ru) | Производные 3,3-биарилпиперидина и 2,2-биарилморфолина | |
| EA200000204A1 (ru) | Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов | |
| EA200101234A1 (ru) | Новые производные аминотиазола, их получение и содержащие их фармацевтические композиции | |
| EA200301317A1 (ru) | Производные аминохинолина и его применение в качестве лигандов аденозина a3 | |
| EA200400848A1 (ru) | Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов | |
| EA200200727A1 (ru) | Новые производные индола | |
| ATE209205T1 (de) | Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |